Factors affecting health-related quality of life among prostate cancer patients: A systematic review

Introduction Prostate cancer is recognized as the leading cause of malignancy-related incidence and mortality in the male population. The treatment regimens have long-term effects detrimental to the patient's quality of life. Hence, this review was aimed to determine the overall HRQOL and its associated among prostate cancer patients. Methods The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The databases searched were PubMed, Embase, Google Scholar and Cumulative Index to the Nursing and Allied Literature (CINAHL), which provided articles that were critically examined, yielding 52 studies that met the inclusion criteria for the systematic review. Results Out of 52 studies, 30 studies reported poor overall HRQOL in various domains after prostate cancer treatment. Contrastingly, 15 studies reported good overall quality of life after treatment. Among the various domains, sexual function was the most grossly affected functional score by the treatment modalities of prostate cancer. Nonetheless, seven studies showed that the absence of a significant change in the overall quality of life after treatment. According to the studies, older age, comorbidities, higher clinical stage, higher Gleason score, greater cancer severity, African American race, impaired mental health, neoadjuvant hormonal therapy and lower level of education were the major poor predictors of HRQOL among prostate cancer patients. Conclusion The overall HRQOL in prostate cancer patients was generally poor in various functional domains after treatment. Among the various domains, sexual function was the most grossly affected functional score by the treatment modalities of prostate cancer.

Download Full-text

The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review

Supportive Care in Cancer ◽

10.1007/s00520-015-2782-x ◽

2015 ◽

Vol 23 (8) ◽

pp. 2479-2497 ◽

Cited By ~ 41

Author(s):

T. Hasenoehrl ◽

M. Keilani ◽

T. Sedghi Komanadj ◽

M. Mickel ◽

M. Margreiter ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Systematic Review ◽

Resistance Exercise ◽

Cancer Patients ◽

Physical Performance ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Download Full-text

USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002–15

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462316000118 ◽

2016 ◽

Vol 32 (3) ◽

pp. 97-106 ◽

Cited By ~ 5

Author(s):

Saku Torvinen ◽

Susanne Bergius ◽

Risto Roine ◽

Leena Lodenius ◽

Harri Sintonen ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Systematic Review ◽

Cancer Patients ◽

Disease Stage ◽

Health Related Quality ◽

Valuation Method ◽

Related Quality ◽

Health Related

Objectives: The objectives of this study were to identify and qualitatively describe, in a systematic literature review, published studies that collected prostate cancer patients’ health-related quality of life (HRQoL) estimates by using validated, generic instruments.Methods: Systematic searches of the literature were made using the Medline, Cochrane Library, PsycINFO, and CINAHL electronic databases from 2002 to 2015.Results: The search identified 2,171 references, of which 237 were obtained for full-text assessment; thirty-three of these articles were deemed relevant and included in the systematic review. An indirect valuation method was used in 73 percent (n = 24) of the studies. The most commonly used HRQoL instrument with an indirect valuation method was the EuroQol (EQ-5D; n = 21), and the second most common was the 15D (n = 5). A direct valuation method was used in 48 percent (n = 16) of the studies. Of these, the Visual Analogue Scale (VAS) was the most often used (n = 10), followed by the Time-Trade-Off (n = 6). HRQoL scores varied in localized and early stage disease between 0.63 and 0.91, and in advanced or metastatic disease stage between 0.50 and 0.87. There was also variance in the HRQoL instruments and study methods used, which explains the large variance in HRQoL scores between the various disease stages.Conclusions: Although utility and quality-adjusted life-years gained are considered important measures of effectiveness in health care, the number of studies in which utilities of prostate cancer patients have been estimated using generic HRQoL instruments, based on either direct or indirect measurement of HRQoL, is fairly small.

Download Full-text

Evaluation of Quality of Life for Prostate Cancer Patients Who Have Undergone Radical Prostatectomy Surgery

American Journal of Men s Health ◽

10.1177/1557988306295024 ◽

2007 ◽

Vol 1 (4) ◽

pp. 284-293

Author(s):

Stephen F. Tomicich

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Radical Prostatectomy ◽

Sexual Function ◽

Cancer Patients ◽

Treatment Option ◽

Surgical Procedure ◽

Treatment Options ◽

Aging Men

Prostate cancer is an epidemic among aging men. It is essential that research be conducted with the purpose of determining the outcomes of various treatment options. For this study, a sample of radical prostatectomy patients completed a written questionnaire for the purpose of evaluating whether the radical prostatectomy for clinically localized prostate cancer has an effect on quality of life. In addition, demographic factors were examined to determine if they had an effect on quality of life after this surgical procedure. Data appeared to show that urinary, bowel, and sexual function are determinants of quality of life that are affected by having the radical prostatectomy procedure. Due to the numerous treatment options available for prostate cancer, more research regarding quality of life should be undertaken to determine the best possible treatment option for the patient.

Download Full-text

A Quality of Life (QOL) Asessment of Genitourinary Toxicity at Three Years for Prostate Cancer Patients Undergoing Different Radiation Treatment Modalities

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2007.07.1873 ◽

2007 ◽

Vol 69 (3) ◽

pp. S585

Author(s):

K.A. Saputo ◽

A. Calcaterra ◽

M. Balasubramaniam ◽

G. Boyea ◽

C. Flynn ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Radiation Treatment ◽

Treatment Modalities ◽

Genitourinary Toxicity

Download Full-text

A review of the effects of tobacco smoking on the treatment of prostate cancer

Journal of Radiotherapy in Practice ◽

10.1017/s1460396920000552 ◽

2020 ◽

pp. 1-8

Author(s):

Faiza Nuru ◽

Ernest Osei ◽

Rahil Kassim

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Smoking Cessation ◽

Radiation Therapy ◽

Cancer Patients ◽

Tobacco Smoking ◽

Treatment Efficacy ◽

Treatment Modalities ◽

Risk Of Cancer

Abstract Background: Prostate cancer is the most commonly diagnosed malignancy and the third leading cause of death among Canadian men. The standard treatment modalities for prostate cancer include prostatectomy, radiation therapy, hormonal therapy and chemotherapy or any combination depending on the stage of the tumour. However, several studies have reported that tobacco smoking at the time of diagnosis and during treatment can potentially impact treatment efficacy, outcome and patients quality of life after treatment. Materials and methods: This narrative literature review elucidates the impacts of tobacco smoking on prostate cancer progression, treatment efficacy, including its effects on prostatectomy, radiation therapy and chemotherapy, risk of cancer recurrence and mortality and quality of life after treatment. Furthermore, we discuss the importance of integrating a smoking cessation programme into the treatment regimen for prostate cancer patients in order to yield more favourable treatment outcomes, reduce risk of recurrence and mortality and increase the quality of life after treatment for prostate cancer patients. Conclusions: Smoking cessation is one of the most important interventions to prevent cancer and it is also essential after the diagnosis of prostate cancer to improve clinical outcomes. All prostate cancer patients should be advised to quit tobacco use since it can potentially improve treatment response rates and survival, as well as reduce the risk of developing treatment complications and potentially improve the quality of life after treatment. There are several benefits to smoking cessation and it should become an important component of the cancer care continuum in all oncology programmes, starting from prevention of cancer through diagnosis, treatment, survivorship and palliative care. Evidence-based smoking cessation intervention should be sustainably integrated into any comprehensive cancer programme, and the information should be targeted to the specific benefits of cessation in cancer patients.

Download Full-text